PCV24 A Threshold Analysis of the Cost-Effectiveness of Adjunctive Inclisiran Therapy for Ascvd Patients with LDL ≥70 MG/DL on Maximally Tolerated Statin Therapy
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI